Oncotelic Highlights Robust Oncology Pipeline with Multiple Late-Stage Candidates
August 28, 2025 — Oncotelic Therapeutics highlights its oncology pipeline with Phase 3 candidates for pancreatic cancer and AML/MDS, plus programs for Parkinson's and rare diseases under CEO Dr. Vuong Trieu's leadership.